Amersin Life Sciences Announces Contract with China’s International Tsunami Relief Program

Share Article

Amersin, a public American holding company, supplies pharmaceuticals for Sri Lanka tsunami relief program under 6.4 million RMB contract through its Chinese subsidiary.

News Image

Amersin Life Sciences Corporation (OTCBB: AMLS), announced today that it’s subsidiary, Hubei Tongji Benda Ebei Pharmaceutical Co. Ltd., has entered into a sales contract valued at 6.4 million RMB with the Ministry of Health’s China Medicine and Technology Foreign Co-operation Co. Ltd.

“This contract is to supply pharmaceuticals to aid Sri Lanka as part of the China’s tsunami relief program,” said Mr. Yiqing Wan, President of the Amersin subsidiary, "we are very pleased to be selected as a supplier and to be part of this international tsunami relief effort. It further illustrates our strong product reputation and relationships with governmental and non-governmental organizations (NGO’s) alike. We would of course prioritize to participate further if called upon or opportunities arise to support other initiatives.”                                    

About Amersin Life Sciences Corporation:

Amersin is engaged in the acquisition and vertical integration of operating subsidiaries and controlling joint venture interests in China to include all facets of pharmaceutical life sciences from research through raw materials and dosage form production to distribution. Its recent acquisition of a controlling interest in the profitable Hubei Tongji Benda Ebei Pharmaceutical Co. subsidiary is a cornerstone in its plan to expand through strategic acquisition and vertical integration to become one of the leading American corporations to profit from the burgeoning life sciences sector in China. Shareholders can access further information via the company's website at http://www.amersin.com.

"Safe Harbor” Statement:

This news release contains certain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from the forward-looking statements contained herein. Detailed information about many risk factors are set forth in Amersin’s periodic filings with the Securities and Exchange Commission including, but not limited to, those risks and uncertainties listed in the sections entitled "Cautionary Note Regarding Forward-Looking Statements” and “Management’s Discussion and Analysis” in Amersin’s most recent Quarterly Report on Form 10-QSB. All documents are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at http://www.sec.gov or the Amersin web site at http://www.amersin.com. Amersin is under no obligation, and expressly disclaims any obligation, to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, please contact:

Howard Milne, Corporate Communications

Amersin Life Sciences Corporation

E-Mail: Howard@amersin.com

Voice: 604-881-2899 ext 220

Fax: 604-881-2892

# # #

Share article on social media or email:

View article via:

Pdf Print